Share This Page
Drug Price Trends for NDC 55111-0135
✉ Email this page to a colleague
Average Pharmacy Cost for 55111-0135
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ZENATANE 10 MG CAPSULE | 55111-0135-81 | 1.68524 | EACH | 2024-12-18 |
| ZENATANE 10 MG CAPSULE | 55111-0135-79 | 1.68524 | EACH | 2024-12-18 |
| ZENATANE 10 MG CAPSULE | 55111-0135-81 | 1.73750 | EACH | 2024-11-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55111-0135
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
55111-0135 Market Analysis and Financial Projection
Market Analysis and Price Projections for Drugs: A Comprehensive Overview
Understanding the National Drug Code (NDC)
To analyze the market and price projections for any drug, including the one identified by the NDC 55111-0135, it is crucial to understand the National Drug Code system. The NDC is a unique, three-segment number that identifies the labeler, product, and trade package size of a drug product. This code is essential for tracking and managing drug products in the healthcare system[1].
Market Trends in Pharmaceutical Pricing
General Pricing Trends
The pharmaceutical market is experiencing significant price increases, particularly in the specialty pharmaceutical sector. According to Vizient, Inc., drug price inflation is projected to grow at 3.8% in 2024, driven largely by specialty pharmacy products, including weight loss drugs and gene therapies[2].
Specialty Pharmaceuticals
Specialty pharmaceuticals, which treat complex or chronic conditions such as cancer, infectious diseases, and autoimmune disorders, are a major contributor to the rising costs. These drugs often have high development and approval costs but also generate substantial revenue. For instance, in 2023, 42 novel specialty drugs were approved, and 2024 is expected to see a record number of approvals, leading to a projected price increase of 4.18% for specialty medications[2].
Factors Influencing Drug Prices
Therapeutic Classes and Pricing
Extraordinary price increases in brand-name drugs often occur within specific therapeutic classes, such as central nervous system agents, anti-infective agents, and cardiovascular agents. Most of these increases are for drugs costing less than $25 per unit, although the total cost of treatment can be several thousand dollars[5].
Repackaging and Pricing
Repackaged brand-name drug products also account for a significant portion of extraordinary price increases. This practice can lead to higher costs for healthcare providers and patients due to the additional layers of distribution and handling[5].
Biosimilars and Their Impact
Biosimilars, which are biologic products that are highly similar to an FDA-approved biological product, are expected to grow in market share. While they currently make up 24.93% of the purchasing volume for originator products and their corresponding biosimilars, they are anticipated to increase their market share as pharmacy benefit managers finalize their formulary strategies. However, biosimilars are expected to see only a 0.55% price increase, which is significantly lower than the increases seen in specialty pharmaceuticals[2].
Development and Approval Costs
The development and approval costs of drugs vary widely depending on the therapeutic area. For example, antimicrobial drugs have lower development and approval costs compared to oncology drugs. On average, antimicrobial drugs cost $1.508 billion to develop and approve, whereas oncology drugs cost $6.293 billion. Despite these costs, drugs with higher comparative clinical benefit scores tend to have higher early market sales[3].
Case Study: Decitabine (NDC 55111-0135)
Decitabine, identified by the NDC 55111-0135, is a sterile, white to almost white lyophilized powder for intravenous use. Here’s how it fits into the broader market analysis:
Market Position
Decitabine is used in the treatment of certain types of cancer, such as myelodysplastic syndromes. Given its therapeutic class, it is likely to be part of the specialty pharmaceutical segment, which is experiencing significant price increases.
Pricing Projections
Given the trend of increasing prices in specialty pharmaceuticals, Decitabine is likely to see price increases in line with other drugs in its therapeutic class. However, the exact magnitude of the price increase would depend on various factors, including the drug's comparative clinical benefit, market competition, and regulatory approvals.
Impact of Biosimilars
While biosimilars are gaining traction, their impact on Decitabine would depend on whether biosimilar versions of this drug are approved and become available in the market. If biosimilars are introduced, they could potentially reduce the price of Decitabine through increased competition.
Regulatory Environment
FDA Approval and NDC
The FDA plays a critical role in the approval and regulation of drug products. The NDC assigned to Decitabine (55111-0135) indicates that it has been approved by the FDA for marketing, ensuring it meets safety and effectiveness standards[1].
Market Performance Metrics
The market performance of Decitabine can be evaluated using metrics such as cumulative global sales since market launch and comparative clinical benefit scores. These metrics help in understanding how the drug performs relative to other drugs in its therapeutic class[3].
Key Takeaways
- Specialty Pharmaceuticals: These drugs, including those like Decitabine, are driving the increase in pharmaceutical costs due to their high development and treatment costs.
- Biosimilars: While biosimilars are expected to grow in market share, their impact on specific drugs like Decitabine will depend on the availability of biosimilar versions.
- Regulatory Environment: FDA approval and the NDC system are crucial for ensuring the safety and effectiveness of drug products.
- Market Trends: The pharmaceutical market is experiencing significant price increases, particularly in the specialty sector, which affects drugs like Decitabine.
FAQs
What is the National Drug Code (NDC), and how is it used?
The NDC is a unique, three-segment number that identifies the labeler, product, and trade package size of a drug product. It is used to track and manage drug products in the healthcare system[1].
Why are specialty pharmaceuticals driving up drug costs?
Specialty pharmaceuticals treat complex or chronic conditions and have high development and approval costs, leading to higher prices. Additionally, the increasing utilization of these drugs contributes to rising healthcare expenditures[2].
How do biosimilars affect the pricing of brand-name drugs?
Biosimilars can reduce the prices of brand-name drugs by introducing competition. However, their impact depends on the availability of biosimilar versions and their adoption in the market[2].
What factors contribute to extraordinary price increases in brand-name drugs?
Factors include therapeutic class, cost per unit, and repackaging. Most extraordinary price increases occur in central nervous system agents, anti-infective agents, and cardiovascular agents, and often involve drugs costing less than $25 per unit[5].
How do development and approval costs vary across different therapeutic areas?
Development and approval costs vary significantly, with antimicrobial drugs having lower costs compared to oncology drugs. On average, antimicrobial drugs cost $1.508 billion to develop and approve, while oncology drugs cost $6.293 billion[3].
Sources
- FDA: National Drug Code Database Background Information - FDA
- Vizient, Inc.: Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals
- ASPE: Antimicrobial Drugs Market Returns Analysis
- DailyMed: DECITABINE injection, powder, lyophilized, for solution
- GAO: Brand-Name Prescription Drug Pricing
More… ↓
